Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday.
Pieris Pharmaceuticals Stock Performance
Shares of NASDAQ PIRS opened at $1.40 on Thursday. The company has a 50-day moving average of $1.07 and a 200 day moving average of $1.30. Pieris Pharmaceuticals has a 12-month low of $0.85 and a 12-month high of $3.75. The stock has a market cap of $104.17 million, a PE ratio of -2.98 and a beta of 0.95.
Get Pieris Pharmaceuticals alerts:Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Pieris Pharmaceuticals had a negative return on equity of 75.31% and a negative net margin of 121.78%. The firm had revenue of $5.37 million during the quarter, compared to analysts' expectations of $4.51 million. On average, sell-side analysts forecast that Pieris Pharmaceuticals will post -0.63 EPS for the current fiscal year.
Institutional Investors Weigh In On Pieris Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cutter & CO Brokerage Inc. grew its stake in shares of Pieris Pharmaceuticals by 1.5% in the 2nd quarter. Cutter & CO Brokerage Inc. now owns 412,229 shares of the biotechnology company's stock valued at $771,000 after buying an additional 6,000 shares during the period. Rafferty Asset Management LLC increased its stake in Pieris Pharmaceuticals by 32.3% during the second quarter. Rafferty Asset Management LLC now owns 29,622 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 7,240 shares during the last quarter. Hsbc Holdings PLC increased its stake in Pieris Pharmaceuticals by 55.6% during the first quarter. Hsbc Holdings PLC now owns 20,556 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 7,343 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Pieris Pharmaceuticals in the first quarter valued at $32,000. Finally, Blair William & Co. IL lifted its stake in shares of Pieris Pharmaceuticals by 9.1% in the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company's stock valued at $390,000 after purchasing an additional 10,760 shares during the last quarter. 47.31% of the stock is currently owned by institutional investors and hedge funds.Pieris Pharmaceuticals Company Profile
(Get Rating)
Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Recommended Stories
- Get a free copy of the StockNews.com research report on Pieris Pharmaceuticals (PIRS)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.